Related Experiment Video
Updated: May 5, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Prognosis of patients with heart failure and reduced ejection fraction in China
Yu Xu1, Yanan Shi, Zhongyu Zhu
1Department of Cardiology, Henan Province People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China.
Insights
Patients with heart failure with reduced ejection fraction (HFrEF) in China face poor prognoses, especially those with left ventricular ejection fraction (LVEF) ≤35%. Optimal medication use and guideline adherence are crucial for improving survival rates in these patients.
Area of Science:
- Cardiology
- Internal Medicine
- Public Health
Background:
- Chronic heart failure (HF) with reduced ejection fraction (HFrEF) poses a significant health burden globally.
- Understanding survival rates and medication adherence in specific populations, like Chinese patients, is critical for effective management.
- Reduced ejection fraction (HFrEF) is a key indicator of cardiac dysfunction and impacts patient prognosis.
Purpose of the Study:
- To investigate the 5-year survival and medication status of patients with HFrEF in China.
- To identify predictors of mortality in this patient cohort.
- To compare outcomes between patients with different levels of reduced ejection fraction (LVEF ≤35% vs. LVEF 36-45%).
Main Methods:
- Single-center, retrospective study enrolling 685 patients with HFrEF (LVEF ≤45%).
- Patients were divided into two groups: LVEF ≤35% (n=371) and LVEF 36-45% (n=314).
- Follow-up for a median of 31 months; Cox regression and Kaplan-Meier analyses were used to assess mortality predictors and survival times.
Main Results:
- Overall mortality was 28% (19% due to pump failure, 6% sudden death).
- Predictors of all-cause mortality included advanced age, higher BMI, advanced New York Heart Association functional class, and lack of oral beta-blockers at discharge.
- Only 24% of patients on ACEI/ARB and 23% on beta-blockers reached maximum tolerated doses.
Conclusions:
- Patients with HFrEF in China exhibit poor prognoses, particularly those with LVEF ≤35%.
- Effective management requires optimizing medication titration (ACEI/ARB, beta-blockers) and adherence to HF guidelines.
- Cardiologists must prioritize guideline-based diagnosis and treatment to improve outcomes for Chinese HF patients.
Abstract:
The present study aimed to investigate the 5-year survival and medication status of patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) in China. This study is a single-center, retrospective study and patients with HF and a left ventricular ejection fraction (LVEF) of ≤45%, were consecutively enrolled. The study population of 685 patients was divided into two groups, namely, LVEF ≤35 (n=371) and LVEF 36-45% (n=314). The patients were followed up for a median of 31 months (range, 8-61 months) and during this period, 24% of patients receiving angiotension-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) treatment and 23% of those receiving β-blockers reached the maximum tolerated dose. Of the 191 total mortalities (28%), 127 were due to pump failure (19%) and 42 (6%) were sudden deaths. A Cox proportional hazards regression model was used to identify the variables associated with the risk of mortality. Kaplan-Meier curves and log-rank tests were used to compare the survival times of patients in the LVEF ≤35% and LVEF of 36-45% groups. The predictors of all-cause mortality were advanced age, body mass index, New York Heart Association functional class and lack of oral β-blockers at discharge. Patients with HFrEF have poor prognoses in China, particularly those patients with an LVEF of ≤35%. Therefore, cardiologists should strive to improve the prognosis of HF among Chinese patients and focus on the importance of the practical application of HF diagnosis and treatment guidelines.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
